Search

everythinglearnresearchcommunity

for

Search:↓

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The user is considering starting Minoxidil and is looking for a topical solution to combine with it. They are confused about which product to prioritize among options like RU58841, Pyrilutamide, FinaTopic, and DutaTopic.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The user is using 1mg oral finasteride, 1.25mg oral minoxidil nightly, and ketoconazole shampoo weekly for hair loss, reporting no side effects. They self-prescribed after inconsistent use of topical minoxidil, using Lonitab from Intas pharmaceutical.

Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.

Nanoxidil is considered by some as a substitute for Minoxidil, but users report it as ineffective and expensive. Finasteride is recommended as a more effective treatment, often used with Minoxidil, microneedling, and ketoconazole.

Someone looking for solutions to their hair loss, who has tried and failed to tolerate anti-androgen treatments such as finasteride, CB-03-01, RU58841, and Eucapil. The user is seeking advice and understanding of their extreme sensitivity to these treatments.

The conversation discusses hair loss treatments, focusing on alternatives to Minoxidil, such as Bimatoprost and Latanoprost, and the use of Finasteride, Dutasteride, RU58841, and microneedling. The user plans to add Latanoprost to their regimen, which already includes oral and topical Minoxidil and Finasteride, Ketoconazole shampoo, and microneedling.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

The conversation discusses using RU58841, a research chemical, for hair loss treatment. The user plans to use it due to side effects from finasteride and minoxidil, despite skepticism about its effectiveness and lack of FDA approval.

A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

Oral Minoxidil can cause puffy eyes and fluid retention. Adding an ACE inhibitor or ARB, like Telmisartan, may help mitigate these side effects.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.

The user is considering whether to add RU58841 or Nizoral shampoo to their current hair loss treatment of finasteride and minoxidil, noting budget constraints and concerns about hair dryness. They are unsure if RU58841 is worth adding or if they should use both treatments to see the effects.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

The user experienced side effects like shallow breathing, loss of libido, and erectile issues after using topical finasteride with minoxidil for hair loss. They are considering whether to continue the treatment despite these side effects.

Research and science related to a minor improvement in hair growth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

RU58841's side effects may be exaggerated due to anxiety, with some users experiencing no issues and others reporting symptoms like chest pain. RU58841, minoxidil, and finasteride are used for hair loss treatment, with varying individual reactions.

Hair loss treatments Fin and Minoxidil failed for user. Suggested alternatives are 75mg oral spiro and RU58841, but concerns about low testosterone and self-esteem were raised.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Minoxidil and finasteride work through different mechanisms; minoxidil-dependent hair requires continued use to maintain growth, while finasteride prevents further hair loss but cannot sustain minoxidil gains alone. Current treatments like minoxidil, finasteride, and others need indefinite use, as no permanent solution exists yet.

The conversation concludes that over-the-counter DHT blockers, like Saw Palmetto, are largely ineffective for hair loss. Finasteride and Minoxidil are recommended as more effective treatments.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.